

**The influence of HLA genotyping on the clinical  
expression and predicting response to treatment in  
juvenile rheumatoid arthritis**

**Thesis**

*Submitted in the Partial Fulfillment of Requirements of  
MD Degree in Pediatrics*

**By**

**Taher Ismail Osman Ayoub**

*(MB; BCh; MS in Pediatrics)*

*Ain Shams University*

**Supervised**

**By**

***Professor Dr. Khaled Salah Awwad***

Professor of Pediatrics

Faculty of Medicine - Ain Shams University

***Dr. Mohamed Hesham Mohamed Ezzat***

***Abd El-Hameed***

Assistant Professor of Pediatrics

Faculty of Medicine - Ain Shams University

***Dr. Kareem Yehia Aly Shaheen***

Assistant Professor of Clinical Pathology

Faculty of Medicine - Ain Shams University

***Dr. Sameh Mohamed Abdel-Wahab***

Assistant Professor of Radiodiagnosis

Faculty of Medicine - Ain Shams University

**Faculty of Medicine**

**Ain Shams University**

**2005**

**تأثير التطبيع الوراثى للأنتيجينات المضادة على المنظور الفحصى و  
تحديد مدى الإستجابة للعلاج فى مرض الروماتويد المفصلى فى الأطفال**

**رسالة مقدمة من**

**الطبيب / طاهر إسماعيل عثمان أيوب**

**ماجستير طب الأطفال - جامعة عين شمس**

**توطئة للحصول على درجة الدكتوراه فى طب الأطفال**

**تحت إشراف**

**الأستاذ الدكتور / خالد صلاح عواد**

**أستاذ طب الأطفال**

**كلية الطب . جامعة عين شمس**

**د. / محمد هشام محمد عزت عبد الحميد**

**أستاذ مساعد طب الأطفال**

**كلية الطب . جامعة عين شمس**

**د. / كريم يحيى على شاهين**

**أستاذ مساعد الباثولوجيا الإكلينيكية**

**كلية الطب . جامعة عين شمس**

**د. / سامح محمد عبد الوهاب**

**أستاذ مساعد الأشعة التشخيصية**

**كلية الطب . جامعة عين شمس**

**كلية الطب**

**جامعة عين شمس**

**2005**

## **Acknowledgments**

الحمد لله رب العالمين

*At first and foremost thanks to “Allah” who gave me the power to finish this work.*

*I find no words by which I can express my deepest thanks and gratitude to my honored professor, **Professor Dr. Khaled Salah Awwad, professor of Pediatrics and professor of Allergy and Immunology, Faculty of Medicine, Ain Shams University,** for the continuous kind encouragement, support and guidance, he gave me throughout the entire work. It has been an honor and privilege to work under his generous supervision.*

*I would like to express my endless gratitude and appreciation to Assist. **Prof. Dr. Mohamed Hesham Mohamed Ezzat Abd El-Hameed,** assistant professor of pediatrics, Ain Shams University, for giving me the opportunity to work under his meticulous supervision. His honest assistance and patience make me truly indebted to him.*

*The sincere help and enormous effort of Assist. **Prof. Dr. Kareem Yehia Aly Shaheen,** assistant professor of clinical pathology, Ain Shams University is truly acknowledged. He gave me a lot of his valuable time to achieve the laboratory part of this work.*

*I am also grateful to Assist. Prof. Dr. Sameh Mohamed Abdel-Wahab, Assistant Professor of Radiodiagnosis, Ain Shams University for his kind effort and support that made achievement of this work possible.*

*To my parents, my wife, my children, colleagues and to every one who participated in a way or another in this work, I owe my thanks and appreciation.*

*A great deal of my gratitude goes to my children and their parents for their kind cooperation and patience wishing them a very rapid and complete permanent recovery.*

***Taher Ismail Osman Ayoub***

## **CONTENTS**

	<i>Page</i>
<i>List of Abbreviations</i>	iv
<i>List of Tables</i>	vi
<i>List of Figures</i>	viii
<b>Introduction and Aim of the work</b>	<b>1</b>
<b>Review of literature</b>	<b>5</b>
<i>Juvenile Rheumatoid Arthritis (JRA)</i>	<b>5</b>
<i>Human Leukocyte Antigens (HLA)</i>	<b>56</b>
<b>Subjects and Methods</b>	<b>77</b>
<b>Results</b>	<b>102</b>
<b>Discussion</b>	<b>127</b>
<b>Recommendations</b>	<b>153</b>
<b>Summary</b>	<b>154</b>
<b>References</b>	<b>159</b>
<b>Arabic summary</b>	<b>---</b>



## ***LIST OF ABBREVIATIONS***

AA protein	: Amyloid A Protein
ACCP	: Anti-cyclic citrullinated peptide
ACR	: American College of Rheumatology
AGEs	: Advanced Glycation End Products
AIDS	: Acquired Immunodeficiency Syndrome
AKA	: Antikeratin antibody
ANA	: Antinuclear antibodies
Ang	: Angiopoietin
APF	: Antiperinuclear factor
APR	: Acute-phase reactants
BMC	: Bone mineral content
BMD	: Bone mineral density
CRP	: C-Reactive Protein
CVD	: Collagen Vascular Disease
DPA	: Dual photon absorptiometry
DXA	: Dual energy X-ray absorptiometry
EBV	: Epstein-Barr Virus
EGF	: Epidermal growth factor
EIA	: Enzyme Immuno-assay
ESR	: Erythrocyte sedimentation rate
FDA	: Food Drug Administration
FGF	: Fibroblast growth factor
GAGs	: Glycosaminoglycans
G-CSF	: Granulocyte colony-stimulating
GM-CSF	: Granulocyte-macrophage colony-stimulating factor
gp	: Glycoprotein
HGF	: Hepatocyte growth factor
HIF-1	: Hypoxia-inducible factor-1
HIV	: Human Immunodeficiency Virus
HLA	: Human Leucocyte Antigen
Hp	: Haptoglobin
HSP	: Heat shock proteins
IGF-1	: Insulin-like Growth Factor-1

Igs	: Immunoglobulins
IL	: Interleukin
IP-10	: Interferon-inducible protein-10
JRA	: Juvenile rheumatoid arthritis
KDa	: Kilo Dalton
MHC	: Major Histocompatibility Complex
MIG	: Monokine induced by interferon- $\gamma$
MMPs	: Matrix metalloproteinases
MRI	: Magnetic Resonance Imaging
NK	: Natural killer
NSAIDs	: Non-steroidal antiinflammatory drugs
PD-ECGF	: Platelet-derived endothelial cell growth factor
PDGF	: Platelet-derived growth factor
PF-4	: Platelet factor-4
PGs	: Proteoglycans
QCT	: Quantitative computed tomography
QUS	: Quantitative ultrasound
RA	: Rheumatoid arthritis
RF	: Rheumatoid factor
RFLP	: Restriction Fragment Length Polymorphism
TGF	: Transforming growth factor
TIMP	: tissue inhibitors of metalloproteinases
TNF- $\alpha$	: Tumor necrosis factor- $\alpha$
VEGF	: Vascular endothelial growth factor

## ***LIST OF TABLES***

<b>Table</b>	<b>Subject</b>	<b>Page</b>
<b>Table (1)</b>	Possible Infectious Causes of JRA	<b>7</b>
<b>Table (2)</b>	Potential autoantigens in RA	<b>10</b>
<b>Table (3)</b>	Angiogenic Inducers and Inhibitors	<b>17</b>
<b>Table (4)</b>	Comparison of Onset Types in JRA	<b>26</b>
<b>Table (5)</b>	Clinical Outcome in JRA by Onset Type and Course Subtype	<b>29</b>
<b>Table (6)</b>	Objectives of the Conservative Management of JRA	<b>36</b>
<b>Table (7)</b>	Drug Therapy of JRA	<b>38</b>
<b>Table (8)</b>	A New Approach to the Treatment of JRA	<b>42</b>
<b>Table (9)</b>	Number of alleles in the human MHC (HLA region)	<b>62</b>
<b>Table (10)</b>	MHC-associated autoimmune disorders	<b>73</b>
<b>Table (11)</b>	Summed Joint Index Score	<b>80</b>
<b>Table (12)</b>	The Characteristics of the Control Group	<b>102</b>
<b>Table (13)</b>	Clinical Data of the Studied JRA Patients	<b>103</b>
<b>Table (14)</b>	Laboratory and Radiological Characteristics of JRA Group	<b>105</b>
<b>Table (15)</b>	Descriptive Data of JRA Patients	<b>107</b>
<b>Table (16)</b>	Frequency Distribution of HLA-DRB1 Alleles in Egyptian Children with JRA and in controls	<b>109</b>
<b>Table (17)</b>	Effect of Gene-Dose on Susceptibility to Juvenile Rheumatoid Arthritis among Egyptian Children	<b>115</b>

## ***LIST OF TABLES***



<b>Table</b>	<b>Subject</b>	<b>Page</b>
<b>Table (18)</b>	Individual HLA-DRB1 Specificities Associated with Susceptibility to Juvenile Rheumatoid Arthritis among Egyptian Children according to Gene-Dose	<b>117</b>
<b>Table (19)</b>	Shared-epitope Sequences Associated with Susceptibility to Juvenile Rheumatoid Arthritis among Egyptian Children according to Gene-Dose	<b>118</b>
<b>Table (20)</b>	HLA-DRB1 alleles among Juvenile Rheumatoid Arthritis Children with and without deformities and erosions	<b>121</b>
<b>Table (21)</b>	The Effect of Shared-epitope according to Gene-Dose on Bone Mineral Density among Juvenile Rheumatoid Arthritis Children	<b>123</b>
<b>Table (22)</b>	The predictive value of SE alleles for response to therapy among JRA children	<b>124</b>

## ***LIST OF FIGURES***

<b>Figure</b>	<b>Subject</b>	<b>Page</b>
---------------	----------------	-------------

<b>Figure (1)</b>	A simplified scheme of inflammatory mediators showing the “hierarchy” of cytokines	<b>25</b>
<b>Figure (2)</b>	The schematic representation of MHC class I and II proteins	<b>58</b>
<b>Figure (3)</b>	Side view diagrammatic structure of a class I MHC Molecule	<b>59</b>
<b>Figure (4)</b>	Peptide-binding sites of MHC class I and class II molecules	<b>60</b>
<b>Figure (5)</b>	Organization of the HLA gene complex on the short arm of human chromosome 6. Regions encoding the class I and class II MHC proteins are indicated by braces	<b>63</b>
<b>Figure (6)</b>	Pathway of assembly and transport for antigen MHC complexes containing class I and class II	<b>66</b>
<b>Figure (7)</b>	Principle of the INNO-LiPA HLA typing test procedure	<b>88</b>
<b>Figure (8)</b>	Typing strip for the LiPA HLA-DRBI	<b>97</b>
<b>Figure (9)</b>	Incidence of the Different Risky Alleles in the Control Group	<b>112</b>
<b>Figure (10)</b>	Incidence of the Different Risky Alleles in Juvenile Rheumatoid Arthritis Patients	<b>113</b>
<b>Figure (11)</b>	The contribution to Juvenile Rheumatoid Arthritis Susceptibility among Egyptian Children compared to controls according to Gene-Dose	<b>116</b>
<b>Figure (12)</b>	The Effect of Shared-epitope according to Gene Dose on Bone Deformities and Erosions among Juvenile Rheumatoid Arthritis Children	<b>122</b>
<b>Figure (13)</b>	Examples of HLA-DRB1 Genotyping in Children with JRA using the INNO-LIPA Strips	<b>125</b>
<b>Figure (14)</b>	QCT scan of lumbar spine.	<b>126</b>

-----*Aim Of*  
*The Work* ---

## **Aim of the Work**

The aim of the present study is to detect the frequency prevalence of HLA-DRB1 genes, to study the influence of such alleles on JRA susceptibility/resistance among a group of Egyptian children having polyarticular onset JRA. Also, the contribution and association of the shared epitope positive HLA-DRB1 alleles (alleles containing QKRAA, QRRAA, and RRRRAA) with disease severity variables, (clinical and radiological destructive arthritis). Also, to determine the predictive value of shared epitope alleles for response to therapy.

## **INTRODUCTION**

HLA class II antigens, HLA-DR, -DQ, and -DP, are heterodimeric glycoproteins consisting of an  $\alpha$  and a  $\beta$  chain. They are cell-surface molecules, mainly expressed on B cells, activated T cells, antigen-presenting cells, and thymic epithelium. They play a role in the presentation of foreign antigens to T cells to start an adequate immune response. They are also involved in the development of specific immune recognition of self. Additionally, they play a crucial role in transplantation immunology and in the susceptibility of autoimmune diseases (*Kinikli et al., 2003*).

The HLA class II genes are located on the short arm of chromosome 6. Both the HLA-DQ and -DP regions contain one functional gene for each of their  $\alpha$ - and  $\beta$ -chains (DQA1 and DQB1; DPA1 and DPB1). For HLA-DR, one gene coding for the DR  $\alpha$ -chain, DRA, and one gene coding for the  $\beta$ -chain, DRB1, is always present. Depending on the DRB1-type, a DRB3, DRB4, or DRB5 may be present, and may be accompanied by pseudogenes (*Brodsky, 2001*).

Among the  $\alpha$ -chain loci, the DQA1 and DPA1 locus show some polymorphism with respectively 19 and 13 alleles. The  $\beta$ -chain loci however, are highly polymorphic. Population surveys in a variety of human populations have identified over 80 alleles at the DPB1 locus, over 35 alleles at the DQB1 locus, and over 195 at the DRB1 locus. Virtually all of the sequence diversity is localized on the second exon, encoding the amino-terminal extracellular domain which functions as the peptide-

-----  
**-Introduction -**

binding groove formed by the  $\alpha$ - $\beta$  heterodimer (*Weyand and Goronzy, 2002*).

With respect to the multiple functions of the HLA class II antigens, adequate typing protocols are extremely important. Matching for solid organ and for bone marrow transplantation, typing for diseases susceptibility, for population studies, as well as for paternity or other forensic investigations are all applications demanding an accurate but simple typing technique (*Thiel and Radbruch, 1999*).

For many of rheumatic diseases, genetic susceptibility is an important member of a triad of triggering factors implicated in pathogenesis. This genetic contribution is an important determinate of disease susceptibility but does not act alone. Environmental contributions and developmental factors act in contact to trigger disease. Thus disease susceptibility genes are best reviewed as permissive for disease.

The association between rheumatoid arthritis (RA) and class II major histocompatibility complex markers was first recognized in 1978. Juvenile RA (JRA) is a polygenic disorder to which the HLA region contributes about 30% of the genetic component. It is strongly associated in most populations and ethnic groups with a certain series of HLA-DRB1 alleles encoding a conserved sequence of amino acids between positions 70 and 74 in the third hypervariable region of DRB1 chain, (<sup>70</sup>Q/R K/R R A A<sup>74</sup>). The binding site of these antigen-presenting molecules is often referred to as the shared epitope (SE). The strongest associations are with certain HLA-DRB1\*04 alleles (\*0401, \*0404, \*0405 and \*0408) but other SE-positive DRB1 alleles (\*0101, \*0102 and \*1001) are also associated with RA (*Wollheim et al., 2003*).

-----  
**-Introduction -**

HLA-DR4 is associated with RA in populations of Northern European ancestry, and the \*0401 allele is the most frequent DR4 subtype. This shared epitope has also been found to be associated with disease severity, especially when present in a double dose. However, because about 30% of patients are negative for DRB1\*04 and 15% are SE negative, a unifying pathological mechanism has proven elusive. On the contrary, in Chilean patients the disease is only weakly associated with HLA-DR4. Among Greeks, Spaniards, Israeli Jews, and African blacks, RA is associated with DR1 and DR10, while among North American Natives; the RA-linked marker is DR14. HLA-DR9, which lacks the shared epitope, represented a novel disease marker. However, it was in only 20% of patients and apparently makes no contribution to severity (*Harney et al., 2003*).

In addition to their role in JRA susceptibility, DRB1 alleles that contain the shared sequences are associated with more severe erosions. These insights into the genetics of JRA were made possible by observations in subjects from a variety of ethnic backgrounds, underscoring the importance of studying JRA susceptibility in diverse populations (*Brintnell et al., 2004*).

## JUVENILE RHEUMATOID ARTHRITIS

### Epidemiology

Rheumatoid arthritis (RA) is the most common chronic inflammatory and destructive arthropathy that cannot be cured and that has substantial personal, social, and economic costs. The long-term prognosis is poor: 80 percent of affected patients are disabled after 20 years, and life expectancy is reduced by an average of 3 to 18 years (*Heiberg et al., 2005*).

RA affects about 1 percent of the general population worldwide. Juvenile RA (JRA) is the most common rheumatic disease in children. It is one of the most frequent chronic illnesses of childhood (*Choy and Panayi, 2001*). The incidence of JRA is approximately 13.9/100,000 children (16 years or less) per year with a prevalence of approximately 113/100,000 children (*Schaller, 1997*). In Egypt, *El-Gamal, (1998)*, reported a frequency prevalence of 9.8 JRA patients per year per 100,000 children attending the outpatients' clinics, Children's Hospital, Ain Shams University.

Although RA is properly considered a disease of the joints, it is important to recognize that it can exhibit a variety of extra-articular manifestations. These manifestations clearly show that RA has features of a systemic disease that is capable of involving a variety of major organ systems. Current slow-acting antirheumatic drugs have limited efficacy and many side effects. Moreover, they do not improve the long-term prognosis of rheumatoid arthritis (*Loetscher and Moser, 2002*).